What arthritis treatments are safe for a patient taking Brilinta (ticagrelor) and aspirin?

Acetaminophen is the safest first-line option for arthritis pain in patients taking Brilinta and aspirin

For patients on dual antiplatelet therapy with Brilinta (ticagrelor) and aspirin, acetaminophen (up to 3,000-4,000 mg daily in divided doses) should be the initial analgesic choice for arthritis pain. This recommendation is based on the critical need to avoid NSAIDs, which significantly increase bleeding risk when combined with antiplatelet agents 1, 2, 3, 2.

Why NSAIDs Are Contraindicated

The cardiovascular guidelines explicitly warn against chronic NSAID use in patients on dual antiplatelet therapy. NSAIDs are listed as medications that increase bleeding risk alongside warfarin, heparin, and fibrinolytic therapy 1, 2. The FDA label for Brilinta reinforces this, noting that concomitant use of medications increasing bleeding risk (including chronic NSAIDs) represents an additional risk factor for bleeding 4.

Even when NSAIDs are considered necessary, the guidelines recommend exhausting other options first. The 2014 AHA/ACC guideline specifically states that before considering NSAIDs, treatment should begin with acetaminophen, nonacetylated salicylates, tramadol, or small doses of narcotics 5.

Stepped-Care Approach for Arthritis Pain

First-Line: Acetaminophen

• Dose: Regular dosing up to 3,000-4,000 mg daily (divided doses)
• Rationale: No antiplatelet interaction, minimal bleeding risk 6, 7, 8
• Caveat: Counsel patients to avoid all other acetaminophen-containing products (OTC cold remedies, combination analgesics) 8

Second-Line Options (if acetaminophen insufficient):

1. Topical NSAIDs (for knee or hand OA)

   • Significantly safer than oral NSAIDs with dual antiplatelet therapy
   • Strong recommendation for knee OA 7
   • Minimal systemic absorption reduces bleeding risk

2. Tramadol (low doses initially)

   • Conditional recommendation for OA 7
   • No antiplatelet interaction
   • Monitor for side effects (dizziness, constipation, dependence risk)

3. Duloxetine

   • Conditional recommendation for knee OA 7, 8
   • No bleeding risk
   • Particularly useful if neuropathic component present

Third-Line: Intra-articular Corticosteroid Injections

• Strong recommendation for moderate-to-severe knee OA pain 6, 7
• No systemic bleeding risk
• Can provide 3-6 months of relief

Non-Pharmacologic Interventions (Essential)

These should be implemented regardless of medication choices:

• Exercise programs (strengthening, aerobic fitness) - strong recommendation 6, 7
• Weight loss if BMI >25 (for knee/hip OA) - strong recommendation 7
• Assistive devices (cane, braces for biomechanical instability) 6
• Physical therapy with manual therapy 6

Critical Pitfalls to Avoid

1. Never use oral NSAIDs routinely - The bleeding risk with dual antiplatelet therapy is substantial. Even if a patient previously tolerated NSAIDs, the addition of Brilinta changes the risk-benefit calculation entirely.

2. Avoid ibuprofen specifically - If an NSAID becomes absolutely necessary (rare), ibuprofen should be avoided as it can interfere with aspirin's cardioprotective effects through pharmacodynamic interaction 8.

3. Do not use COX-2 inhibitors - Despite lower GI bleeding risk, the guidelines recommend against COX-2 inhibitors in patients on dual antiplatelet therapy with aspirin 6, 8.

4. Monitor acetaminophen total daily dose - With maximum dosing, hepatotoxicity risk increases, especially with alcohol use or liver disease.

When NSAIDs Might Be Considered (Extreme Circumstances Only)

If intolerable pain persists despite the stepped-care approach above, and only after documented failure of acetaminophen, topical NSAIDs, tramadol, duloxetine, and intra-articular injections, a nonselective NSAID (NOT ibuprofen, NOT COX-2 inhibitors) at the lowest effective dose for the shortest duration might be considered 5, 8. This requires:

• Mandatory proton pump inhibitor co-prescription 6, 8
• Careful discussion of bleeding risks
• Close monitoring
• Consideration of cardiology consultation

However, this scenario should be rare. The evidence strongly supports that most patients can achieve adequate pain control with the safer alternatives outlined above, particularly when combined with non-pharmacologic interventions 6, 7.